Should I buy or sell Eledon Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eledon Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ELDN shares. View ELDN analyst ratings or view top-rated stocks .

What is Eledon Pharmaceuticals' stock price target for 2024?

3 brokerages have issued 12-month price targets for Eledon Pharmaceuticals' shares. Their ELDN share price targets range from $9.00 to $13.00. On average, they anticipate the company's share price to reach $10.67 in the next year. This suggests a possible upside of 835.7% from the stock's current price. View analysts price targets for ELDN or view top-rated stocks among Wall Street analysts .

How have ELDN shares performed in 2023?

Eledon Pharmaceuticals' stock was trading at $2.28 at the start of the year. Since then, ELDN stock has decreased by 50.0% and is now trading at $1.14. View the best growth stocks for 2023 here .

Are investors shorting Eledon Pharmaceuticals?

Eledon Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 65,900 shares, an increase of 25.8% from the October 31st total of 52,400 shares. Based on an average trading volume of 88,800 shares, the days-to-cover ratio is currently 0.7 days. View Eledon Pharmaceuticals' Short Interest .

When is Eledon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our ELDN earnings forecast .

How were Eledon Pharmaceuticals' earnings last quarter?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) released its earnings results on Thursday, November, 9th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.06.

Who are Eledon Pharmaceuticals' major shareholders?

Eledon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (7.54%), Jmac Enterprises LLC (0.25%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David-Alexandre C Gros, David-Alexandre C Gros and Paul Sean Little. View institutional ownership trends .

How do I buy shares of Eledon Pharmaceuticals?

Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Eledon Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ELDN)

$1.14

-0.01 (-0.87%)

(As of 12/1/2023 ET)

Compare

Today's Range: $1.12
▼
$1.16
50-Day Range: $1.12
▼
$1.69
52-Week Range: $1.07
▼
$3.70

Volume: 38,488 shs
Average Volume: 58,054 shs
Market Capitalization: $27.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.67

Eledon Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 835.7% Upside
$10.67 Price Target
Short Interest: Healthy
0.27% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.89
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.89) to ($1.43) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

377th out of 957 stocks

Pharmaceutical Preparations Industry

165th out of 444 stocks

3.5

Analyst's Opinion

Consensus Rating
Eledon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.67, Eledon Pharmaceuticals has a forecasted upside of 835.7% from its current price of $1.14.
Amount of Analyst Coverage
Eledon Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.27% of the outstanding shares of Eledon Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Eledon Pharmaceuticals has recently increased by 25.76%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Eledon Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Eledon Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ELDN.

3.3

News and Social Media Coverage

News Sentiment
Eledon Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Eledon Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
4 people have searched for ELDN on MarketBeat in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
19.40% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 39.40% of the stock of Eledon Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Eledon Pharmaceuticals are expected to grow in the coming year, from ($1.89) to ($1.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eledon Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eledon Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Eledon Pharmaceuticals has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

ELDN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ELDN Stock News Headlines

November 29, 2023 | finance.yahoo.com

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

November 10, 2023 | finanznachrichten.de

Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

December 3, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 9, 2023 | msn.com

Eledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

November 9, 2023 | finance.yahoo.com

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

November 8, 2023 | finance.yahoo.com

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

November 6, 2023 | markets.businessinsider.com

Promising Results and Buy Rating for Eledon Pharmaceuticals: Tegoprubart’s Potential in Kidney Transplant Therapy

November 4, 2023 | markets.businessinsider.com

Promising Phase Ib Study Results Bolster Buy Rating for Eledon Pharmaceuticals: An Analysis by Rami Katkhuda

December 3, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 2, 2023 | finance.yahoo.com

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

October 24, 2023 | msn.com

HC Wainwright & Co. Maintains Eledon Pharmaceuticals (ELDN) Buy Recommendation

October 23, 2023 | msn.com

Eledon Pharmaceuticals appoints Eliezer Katz as CMO

October 23, 2023 | markets.businessinsider.com

Eledon Pharmaceuticals Appoints Eliezer Katz As Chief Medical Officer

October 23, 2023 | finance.yahoo.com

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

October 13, 2023 | finance.yahoo.com

Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

October 2, 2023 | finance.yahoo.com

Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

September 28, 2023 | nasdaq.com

Noble Capital Markets Initiates Coverage of Eledon Pharmaceuticals (ELDN) with Outperform Recommendation

September 27, 2023 | markets.businessinsider.com

Promising Clinical Trials and Future Projections Bolster Buy Rating for Eledon Pharmaceuticals

September 25, 2023 | finance.yahoo.com

Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

September 20, 2023 | finance.yahoo.com

Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

September 6, 2023 | finance.yahoo.com

Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates

September 5, 2023 | finance.yahoo.com

Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

August 22, 2023 | msn.com

Cantor Fitzgerald Reiterates Eledon Pharmaceuticals (ELDN) Overweight Recommendation

August 16, 2023 | finance.yahoo.com

Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

August 10, 2023 | finance.yahoo.com

Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results

July 17, 2023 | finance.yahoo.com

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

July 12, 2023 | finance.yahoo.com

Amerigo Reports Q2-2023 Production Results and Provides MVC Operational Update

See More Headlines

Receive ELDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/03/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ELDN
CUSIP: N/A
CIK: 1404281
Web: novustherapeutics.com
Phone: (949) 238-8090
Fax: N/A
Employees: 17
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.67
High Stock Price Target: $13.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +835.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-87,970,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -46.18%
Return on Assets: -42.79%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 21.73
Quick Ratio: 21.73

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: $0.70 per share
Price / Cash Flow: 1.62
Book Value: $3.77 per share
Price / Book: 0.30

Miscellaneous

Outstanding Shares: 24,200,000
Free Float: 19,504,000
Market Cap: $27.59 million
Optionable: Not Optionable
Beta: 1.64

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. David-Alexandre C. Gros M.D. (Age 51)
Ph.D., CEO & Non Independent Director
Comp: $807.96k
Dr. Steven N. Perrin Ph.D. (Age 57)
President, Chief Scientific Officer & Non Independent Director
Comp: $603.9k
Mr. Paul Sean Little (Age 58)
CFO & Principal Accounting Officer
Comp: $611.71k
Mr. John Herberger
Vice President of Technical Operations
Mr. Bryan E. Smith J.D. (Age 43)
General Counsel, Corporate Secretary & Chief Compliance Officer
Comp: $377.14k
Dr. David Hovland Ph.D.
Chief Regulatory Officer
Dr. Eliezer Katz F.A.C.S.
FACS, M.D., Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ELDN Stock Analysis - Frequently Asked Questions

Should I buy or sell Eledon Pharmaceuticals stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eledon Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ELDN shares.
View ELDN analyst ratings or view top-rated stocks.
What is Eledon Pharmaceuticals' stock price target for 2024?: 3 brokerages have issued 12-month price targets for Eledon Pharmaceuticals' shares. Their ELDN share price targets range from $9.00 to $13.00. On average, they anticipate the company's share price to reach $10.67 in the next year. This suggests a possible upside of 835.7% from the stock's current price.
View analysts price targets for ELDN or view top-rated stocks among Wall Street analysts.
How have ELDN shares performed in 2023?: Eledon Pharmaceuticals' stock was trading at $2.28 at the start of the year. Since then, ELDN stock has decreased by 50.0% and is now trading at $1.14.
View the best growth stocks for 2023 here.
Are investors shorting Eledon Pharmaceuticals?: Eledon Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 65,900 shares, an increase of 25.8% from the October 31st total of 52,400 shares. Based on an average trading volume of 88,800 shares, the days-to-cover ratio is currently 0.7 days.
View Eledon Pharmaceuticals' Short Interest.

When is Eledon Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ELDN earnings forecast.
How were Eledon Pharmaceuticals' earnings last quarter?: Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) released its earnings results on Thursday, November, 9th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.06.
Who are Eledon Pharmaceuticals' major shareholders?: Eledon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (7.54%), Jmac Enterprises LLC (0.25%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David-Alexandre C Gros, David-Alexandre C Gros and Paul Sean Little.
View institutional ownership trends.
How do I buy shares of Eledon Pharmaceuticals?: Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ELDN) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial